Summary
The Federal Trade Commission (FTC) has accused the three largest pharmacy benefit managers (PBMs) of inflating insulin prices and steering patients toward more expensive insulin products to increase their profits. The FTC argues that PBMs have exploited their position as drug middlemen to drive up prices and make more money, while harming patients who need lifesaving medications. This action comes as insulin prices have been a significant concern for many Americans, and it reflects a broader debate about the role of PBMs in the healthcare system. The FTC is seeking to prohibit PBMs from favoring more expensive drugs based solely on financial incentives, arguing that this practice distorts competition and hurts consumers. This case could have significant implications for drug pricing and the role of PBMs in the healthcare system.
Thanks for listening to Earl’s Newsletter Podcast Subscribe for free to receive new posts and support my work.
